# Ian E Alexander

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 58 papers | 2,565 citations | 22 h-index | 50 g-index |
| 62 ext. papers | 3,174 ext. citations | 8.8 avg, IF | 5.17 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 58 | Novel human liver-tropic AAV variants define transferable domains that markedly enhance the human tropism of AAV7 and AAV8.. *Molecular Therapy - Methods and Clinical Development*, **2022**, 24, 88-101 | 6.4 | 3 |
| 57 | A bioinformatic pipeline for simulating viral integration data.. *Data in Brief*, **2022**, 42, 108161 | 1.2 | 0 |
| 56 | Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118, | 11.5 | 5 |
| 55 | Single amino acid insertion allows functional transduction of murine hepatocytes with human liver tropic AAV capsids. *Molecular Therapy - Methods and Clinical Development*, **2021**, 21, 607-620 | 6.4 | 3 |
| 54 | The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis. *Gastroenterology*, **2021**, 160, 1224-1239.e30 | 13.3 | 26 |
| 53 | Genome editing in the human liver: Progress and translational considerations. *Progress in Molecular Biology and Translational Science*, **2021**, 182, 257-288 | 4 | 0 |
| 52 | The self-peptide repertoire plays a critical role in transplant tolerance induction. *Journal of Clinical Investigation*, **2021**, 131, | 15.9 | 1 |
| 51 | Adeno-Associated Virus Vector Gene Delivery Elevates Factor I Levels and Downregulates the Complement Alternative Pathway. *Human Gene Therapy*, **2021**, 32, 1370-1381 | 4.8 | 1 |
| 50 | Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys. *Molecular Therapy - Methods and Clinical Development*, **2021**, 23, 135-146 | 6.4 | 4 |
| 49 | Isling: a tool for detecting integration of wild-type viruses and clinical vectors.. *Journal of Molecular Biology*, **2021**, 167408 | 6.5 | 1 |
| 48 | Angiotensin Converting Enzyme-2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver.. *Hepatology Communications*, **2021**, | 6 | 1 |
| 47 | Great expectations: virus-mediated gene therapy in neurological disorders. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 849-860 | 5.5 | 10 |
| 46 | Attenuation of Heparan Sulfate Proteoglycan Binding Enhances Transduction of Human Primary Hepatocytes with AAV2. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 1139-1154 | 6.4 | 12 |
| 45 | High-Throughput , and Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction. *Human Gene Therapy*, **2020**, 31, 575-589 | 4.8 | 26 |
| 44 | Efficient editing of OTC-deficient patient-derived primary human hepatocytes. *JHEP Reports*, **2020**, 2, 100065 | 10.3 | 8 |
| 43 | Use of a Hybrid Adeno-Associated Viral Vector Transposon System to Deliver the Insulin Gene to Diabetic NOD Mice. *Cells*, **2020**, 9, | 7.9 | 4 |
| 42 | Restoring the natural tropism of AAV2 vectors for human liver. *Science Translational Medicine*, **2020** , 12, | 17.5 | 14 |

| | | | |
|---|---|---|---|
| 41 | Systemic AAV8-mediated delivery of a functional copy of muscle glycogen phosphorylase (Pygm) ameliorates disease in a murine model of McArdle disease. *Human Molecular Genetics*, **2020**, 29, 20-30 | 5.6 | 4 |
| 40 | The implementation of newborn screening for spinal muscular atrophy: the Australian experience. *Genetics in Medicine*, **2020**, 22, 557-565 | 8.1 | 36 |
| 39 | AAV-Mediated Gene Delivery to the Mouse Liver. *Methods in Molecular Biology*, **2019**, 1937, 213-219 | 1.4 | 5 |
| 38 | Prevention of Cholestatic Liver Disease and Reduced Tumorigenicity in a Murine Model of PFIC Type 3 Using Hybrid AAV-piggyBac Gene Therapy. *Hepatology*, **2019**, 70, 2047-2061 | 11.2 | 14 |
| 37 | Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort. *Human Gene Therapy*, **2019**, 30, 79-87 | 4.8 | 27 |
| 36 | Insights into Gene Therapy for Urea Cycle Defects by Mathematical Modeling. *Human Gene Therapy*, **2019**, 30, 1385-1394 | 4.8 | 9 |
| 35 | A User Guide to the Inverted Terminal Repeats of Adeno-Associated Virus. *Human Gene Therapy Methods*, **2019**, 30, 206-213 | 4.9 | 11 |
| 34 | Codon-Optimization of Wild-Type Adeno-Associated Virus Capsid Sequences Enhances DNA Family Shuffling while Conserving Functionality. *Molecular Therapy - Methods and Clinical Development*, **2019**, 12, 71-84 | 6.4 | 13 |
| 33 | Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors. *Human Gene Therapy*, **2018**, 29, 874-885 | 4.8 | 1 |
| 32 | AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization. *Angiogenesis*, **2018**, 21, 95-109 | 10.6 | 8 |
| 31 | Gene therapy clinical trials worldwide to 2017: An update. *Journal of Gene Medicine*, **2018**, 20, e3015 | 3.5 | 433 |
| 30 | Human Connexin40 Mutations Slow Conduction and Increase Propensity for Atrial Fibrillation. *Heart Lung and Circulation*, **2018**, 27, 114-121 | 1.8 | 8 |
| 29 | Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. *Molecular Therapy*, **2018**, 26, 289-303 | 11.7 | 97 |
| 28 | Direct recognition of hepatocyte-expressed MHC class I alloantigens is required for tolerance induction. *JCI Insight*, **2018**, 3, | 9.9 | 7 |
| 27 | Thymocyte self-renewal and oncogenic risk in immunodeficient mouse models: relevance for human gene therapy clinical trials targeting haematopoietic stem cell populations?. *Mammalian Genome*, **2018**, 29, 771-776 | 3.2 | 2 |
| 26 | Limiting Thymic Precursor Supply Increases the Risk of Lymphoid Malignancy in Murine X-Linked Severe Combined Immunodeficiency. *Molecular Therapy - Nucleic Acids*, **2017**, 6, 1-14 | 10.7 | 15 |
| 25 | Identification of liver-specific enhancer-promoter activity in the 3Tuntranslated region of the wild-type AAV2 genome. *Nature Genetics*, **2017**, 49, 1267-1273 | 36.3 | 55 |
| 24 | Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. *Journal of Inherited Metabolic Disease*, **2017**, 40, 497-517 | 5.4 | 54 |

| | | | |
|---|---|---|---|
| 23 | Ub-ISAP: a streamlined UNIX pipeline for mining unique viral vector integration sites from next generation sequencing data. *BMC Bioinformatics*, **2017**, 18, 305 | 3.6 | 5 |
| 22 | The Potential of AAV-Mediated Gene Targeting for Gene and Cell Therapy Applications. *Current Stem Cell Reports*, **2015**, 1, 16-22 | 1.8 | 6 |
| 21 | Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs. *Cell Stem Cell*, **2015**, 16, 367-72 | 18 | 53 |
| 20 | Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyBac transposase gene delivery system. *Hepatology*, **2015**, 62, 417-28 | 11.2 | 21 |
| 19 | Coherence analysis discriminates between retroviral integration patterns in CD34(+) cells transduced under differing clinical trial conditions. *Molecular Therapy - Methods and Clinical Development*, **2015**, 2, 15015 | 6.4 | 1 |
| 18 | ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice. *Molecular Therapy* , **2015**, 23, 1434-43 | 11.7 | 47 |
| 17 | Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. *Nature*, **2014**, 506, 382-6 | 50.4 | 279 |
| 16 | The transcriptional and functional properties of mouse epiblast stem cells resemble the anterior primitive streak. *Cell Stem Cell*, **2014**, 14, 107-20 | 18 | 194 |
| 15 | A genome-wide map of adeno-associated virus-mediated human gene targeting. *Nature Structural and Molecular Biology*, **2014**, 21, 969-75 | 17.6 | 9 |
| 14 | Intrahepatic activation of naive CD4+ T cells by liver-resident phagocytic cells. *Journal of Immunology*, **2014**, 193, 2087-95 | 5.3 | 24 |
| 13 | Exploiting the unique regenerative capacity of the liver to underpin cell and gene therapy strategies for genetic and acquired liver disease. *International Journal of Biochemistry and Cell Biology*, **2014**, 56, 141-52 | 5.6 | 3 |
| 12 | Impact of next-generation sequencing error on analysis of barcoded plasmid libraries of known complexity and sequence. *Nucleic Acids Research*, **2014**, 42, e129 | 20.1 | 28 |
| 11 | Gene therapy clinical trials worldwide to 2012 - an update. *Journal of Gene Medicine*, **2013**, 15, 65-77 | 3.5 | 582 |
| 10 | Adeno-associated virus-mediated rescue of neonatal lethality in argininosuccinate synthetase-deficient mice. *Molecular Therapy*, **2013**, 21, 1823-31 | 11.7 | 29 |
| 9 | Gene therapy for tolerance: high-level expression of donor major histocompatibility complex in the liver overcomes naive and memory alloresponses to skin grafts. *Transplantation*, **2013**, 95, 70-7 | 1.8 | 15 |
| 8 | Gene therapy for metabolic disorders: an overview with a focus on urea cycle disorders. *Journal of Inherited Metabolic Disease*, **2012**, 35, 641-5 | 5.4 | 10 |
| 7 | Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery. *Molecular Therapy*, **2011**, 19, 854-9 | 11.7 | 36 |
| 6 | Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. *Molecular Therapy*, **2010**, 18, 965-76 | 11.7 | 46 |

| | | | |
|---|---|---|---|
| 5 | Sexually dimorphic patterns of episomal rAAV genome persistence in the adult mouse liver and correlation with hepatocellular proliferation. *Molecular Therapy*, **2009**, 17, 1548-54 | 11.7 | 30 |
| 4 | AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. *Molecular Therapy*, **2009**, 17, 1340-6 | 11.7 | 71 |
| 3 | Gene delivery to the juvenile mouse liver using AAV2/8 vectors. *Molecular Therapy*, **2008**, 16, 1081-8 | 11.7 | 123 |
| 2 | A novel splice-site mutation in the common gamma chain (gammac) gene IL2RG results in X-linked severe combined immunodeficiency with an atypical NK+ phenotype. *Human Mutation*, **2004**, 23, 522-3 | 4.7 | 30 |
| 1 | The adenovirus E4 ORF6 and E1b 55 kDa proteins cooperate in a p53-independent manner to enhance transduction by recombinant adeno-associated virus vectors. *Journal of General Virology*, **2000**, 81, 2983-2991 | 4.9 | 3 |